One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
A novel hypothesis linking low-grade ketonaemia to cardio-renal benefits with sodium-glucose cotransporter-2 inhibitors
Preethika Ekanayake MD, Sunder Mudaliar MD
doi : 10.1111/dom.14562
Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial
Matthew R. Weir MD, Jagadish Gogate PhD, C.V. Damaraju PhD, Ricardo Correa-Rotter MD, Kenneth W. Mahaffey MD
doi : 10.1111/dom.14539
A single bout of cycling exercise induces nucleosome repositioning in the skeletal muscle of lean and overweight/obese individuals
Prasad P. Devarshi PhD, Andrea S. Pereyra MD, PhD, Jessica M. Ellis PhD, Tara M. Henagan PhD
doi : 10.1111/dom.14541
Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial
Melanie J. Davies MD, Julio Rosenstock MD, Amar Ali MBChB (Hons), David Russell-Jones MD, Elisabeth Souhami MD, Karen Palmer BSc (Hons), Chen Ji PhD, Elisabeth Niemoeller MD, Neil Skolnik MD
doi : 10.1111/dom.14543
Degludec hospital trial: A randomized controlled trial comparing insulin degludec U100 and glargine U100 for the inpatient management of patients with type 2 diabetes
Rodolfo J. Galindo MD, Francisco J. Pasquel MD, Priyathama Vellanki MD, Radica Alicic MD, David W. Lam MD, Maya Fayfman MD, Alexandra L. Migdal MD, Georgia M. Davis MD, Saumeth Cardona MD, Maria A. Urrutia MD, Citlalli Perez-Guzman MD, Karla Walkiria Zamudio-Coronado MD, Limin Peng PhD, Katherine R. Tuttle MD, Guillermo E. Umpierrez MD
doi : 10.1111/dom.14544
Antiobesity therapeutics with complementary dual-agonist activities at glucagon and glucagon-like peptide 1 receptors
Bong Gyu Park PhD, Gyeong Min Kim PhD candidate, Hye-Jin Lee MS, Jae Ha Ryu PhD, Dong-Hoon Kim PhD, Jae-Young Seong PhD, Soojeong Kim PhD, Zee-Yong Park PhD, Young-Joon Kim PhD, Jaemin Lee PhD, Jae Il Kim PhD
doi : 10.1111/dom.14546
Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy
Juan P. FrÃas MD, Jill Maaske MD, Lisa Suchower MA, Lars Johansson PhD, Paul D. Hockings PhD, Nayyar Iqbal MD, John P. H. Wilding DM
doi : 10.1111/dom.14548
Switching the basal insulin to insulin glargine 300 U/ml in people with type 2 diabetes under basal insulin supported oral therapy: Observational trial on effectiveness and safety
Jochen Seufert MD, Peter Wiesli MD, Andreas Fritsche MD, Helmut Anderten MD, Katrin Pegelow PhD, Stefan Pscherer MD, Martin Pfohl MD
doi : 10.1111/dom.14549
Relationship between blood glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics: Subanalysis of a prospective cohort study
Akemi Tokutsu MD, Yosuke Okada MD, Tomoya Mita MD, Keiichi Torimoto MD, Satomi Wakasugi MD, Naoto Katakami MD, Hidenori Yoshii MD, Kohei Uryu MD, Keiko Nishida MD, Tadashi Arao MD, Yoshiya Tanaka MD, Masahiko Gosho PhD, Iichiro Shimomura MD, Hirotaka Watada MD
doi : 10.1111/dom.14550
Gastrointestinal tolerability of once-weekly semaglutide 2.4Â mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
Sean Wharton MD, Salvatore Calanna MD, Melanie Davies MD, Dror Dicker MD, Bryan Goldman MS, Ildiko Lingvay MD, Ofri Mosenzon MD, Domenica M. Rubino MD, Mette Thomsen MD, Thomas A. Wadden PhD, Sue D. Pedersen MD
doi : 10.1111/dom.14551
Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis
Ioannis Avgerinos MD, Thomas Karagiannis MD, Panagiota Kakotrichi MD, Theodoros Michailidis MD, Aris Liakos MD, David R. Matthews MD, Apostolos Tsapas MD, Eleni Bekiari MD
doi : 10.1111/dom.14555
Postprandial renal haemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double-blind trial
Marcel H. A. Muskiet MD, Lennart Tonneijck MD, Mark M. Smits MD, Mark H. H. Kramer MD, D. Margriet Ouwens PhD, Bolette Hartmann PhD, Jens J. Holst PhD, A. H. Jan Danser MD, Jaap A. Joles DVM, Daniël H. van Raalte MD
doi : 10.1111/dom.14557
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial
Peter Rossing MD, Rajiv Agarwal MD, Stefan D. Anker MD, Gerasimos Filippatos MD, Bertram Pitt MD, Luis M. Ruilope MD, Aslam Amod MD, Michel Marre MD, Amer Joseph MBBS, Andrea Lage MD, Charlie Scott MSc, George L. Bakris MD, on behalf of the FIDELIO-DKD Investigators
doi : 10.1111/dom.14558
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial
João Pedro Ferreira MD, Silvio E. Inzucchi MD, Michaela Mattheus Dipl. Biomath, Thomas Meinicke MD, Dominik Steubl MD, Christoph Wanner MD, Bernard Zinman MD
doi : 10.1111/dom.14559
Glucose-dependent insulinotropic polypeptide induces lipolysis during stable basal insulin substitution and hyperglycaemia in men with type 1 diabetes: A randomized, double-blind, placebo-controlled, crossover clinical trial
Sebastian M.N. Heimburger MSc, Chris N. Nielsen MD, Salvatore Calanna MD, PhD, Professor Jens J. Holst MD, DMSc, Professor Tina Vilsbøll MD, DMSc, Professor Filip K. Knop PhD, MD, Associate Professor Mikkel B. Christensen MD, PhD
doi : 10.1111/dom.14545
The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis
Jonathan M. Wilson, Yanzhu Lin, M. Jane Luo, Gary Considine, Amy L. Cox, Lenden M. Bowsman, Deborah A. Robins, Axel Haupt, Kevin L. Duffin, Giacomo Ruotolo
doi : 10.1111/dom.14553
Are novel glucose-lowering agents' cardiorenal benefits generalizable to individuals of Black race? A meta-trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment
Huilin Tang MSc, Stephen E. Kimmel MD, Inmaculada Hernandez PharmD, PhD, Maria M. Brooks PhD, Kenneth Cusi MD, Steven M. Smith PharmD, Weilong Shi MSc, Almut G. Winterstein PhD, Jared W. Magnani MD, Jingchuan Guo MD, PhD
doi : 10.1111/dom.14540
Does poor glycaemic control affect the immunogenicity of the COVID-19 vaccination in patients with type 2 diabetes: The CAVEAT study
Raffaele Marfella MD, Nunzia D'Onofrio BiolD, Celestino Sardu MD, Lucia Scisciola BiolD, Paolo Maggi MD, Nicola Coppola MD, Ciro Romano MD, Vincenzo Messina MD, Fabrizio Turriziani MD, Mario Siniscalchi MD, Mauro Maniscalco MD, Marco Boccalatte MD, Giovanni Napolitano MD, Luigi Salemme MD, Ludovica Vittoria Marfella st, Eugenio Basile MD, Maria Vittoria Montemurro MD, Carmela Papa st, Francesco Frascaria MD, Antonio Papa MD, Ferdinando Russo MD, Virginia Tirino MD, Gianpaolo Papaccio MD, Marilena Galdiero MD, Ferdinando Carlo Sasso MD, Michelangela Barbieri MD, Maria Rosaria Rizzo MD, Maria Luisa Balestrieri BiolD, Italo Francesco Angelillo DDS, MPH, Claudio Napoli MD, Giuseppe Paolisso MD
doi : 10.1111/dom.14547
Pharmacodynamics and pharmacokinetics of extended-release metformin in patients with type 2 diabetes and chronic kidney disease stage 3B
Jean-Daniel Lalau MD, Youssef Bennis MD, Abdallah Al-Salameh MD, Anne-Sophie Hurtel-Lemaire MD, Salha Fendri MD
doi : 10.1111/dom.14554
Off-label use of sodium glucose co-transporter inhibitors among adults in type 1 diabetes exchange registry
Michael S. Hughes MD, Ryan Bailey MS, Peter Calhoun PhD, Viral N. Shah MD, Sarah K. Lyons MD, Daniel J. DeSalvo MD
doi : 10.1111/dom.14556
From insulin injections to islet transplantation: An overview of the journey
Michelle B. Paget BSc(Hons), PhD, Hilary E. Murray BSc, PhD, Clifford J. Bailey PhD, Richard Downing BSc, MD, FRCS
doi : 10.1111/dom.14526
The ongoing evolution of basal insulin therapy over 100 years and its promise for the future
Ravi Retnakaran, Bernard Zinman
doi : 10.1111/dom.14552
Insulin Centennial: Milestones influencing the development of insulin preparations since 1922
David R. Owens MD, Louis Monnier MD, Antonio Ceriello MD, Geremia B. Bolli MD
doi : 10.1111/dom.14587
The automated pancreas: A review of technologies and clinical practice
Torben Biester MD, Martin Tauschmann PhD, Agata Chobot PhD, Olga Kordonouri MD, Thomas Danne MD, Thomas Kapellen MD, Klemen Dovc PhD
doi : 10.1111/dom.14576
Pushing the limits of insulin delivery 100 years later: A case study of a race across Canada
Lauren V. Turner BSc, Michael C. Riddell PhD
doi : 10.1111/dom.14629
Rapid-acting insulin analogues: Theory and best clinical practice in type 1 and type 2 diabetes
Christophe E. M. De Block MD, Jolijn Van Cauwenberghe MD, Niels Bochanen MD, Eveline Dirinck MD
doi : 10.1111/dom.14713
